OxyFile #23


Retrospective benefit following individualized naturopathic 

therapy in HIV-patients at different stages.





Author:  Wolfstadter HD; Sacher J; Hopfenmuller W; Stange R



Address: Universitatsklinikum Steglitz, Freien Universitat Berlin.



Source:  Int Conf AIDS, 1992 Jul 19-24, 8:3, 147 (abstract no. PuB 

         7588)



Abstract:



OBJECTIVE: To assess the long-term efficacy and benefit of a 

complementary treatment regimen, we investigated on laboratory 

findings and clinical outcome in a cohort of 175 out-patients (CDC 

II-IV E) successively treated since 1986. METHODS AND PATIENTS: 

The therapeutic regimen comprised autologous ozone transfusions, 

homeopathy, phytotherapy, therapy with enzymes, mineral-, vitamin- 

and trace element substitution, nutritional management, correction 

of intestinal dysbacteria and psychophysical means, set up on an 

individualized basis. No conventional antiviral therapy was given. 

Patients (all male homosexuals) were divided into 5 groups (Gr. I-

V) according to their CD4 lymphocyte counts at entry into therapy 

(Gr.I n = 22, CD4 0-50; Gr. II n = 12, CD4 51-100; Gr. III n = 17, 

CD4 101-200; Gr. IV n = 81, CD4 201-500; Gr. V n = 53, CD4 greater 

than 500 [/microliters]) and 15 hematological and biochemical 

parameters were evaluated with individual regression analysis 

according to the length of observation of patients (min. obs.time 

in Gr. I-III 3 months, min. obs.time in Gr. IV and V 6 months). 

Moreover we studied the incidence and severity of opportunistic 

infections and overall QOL during the observed period. RESULTS: 

Patients in Gr. I presented a median loss of CD4 lymphocytes per 

month of 0.54 cells/microliters(range -42.0 to 4.50, median 

obs.time 8 months), Gr. II median loss 3.65 cells/microliters 

(range -5.9 to 8.8, median obs.time 10.5 mo.), Gr. III median loss 

4.98 cells/microliters (range -13.5 to 11.0, median obs.time 16.8 

mo.). In Gr. V, apparently due to the earlier stage of disease, no 

clear statistical trend of helper-cell deterioration could be 

observed. Patients in Gr. IV, with an approved indication for 

antiviral therapy, presented a median loss of CD4-cells of 

4.47/microliters (range -17.2 to 37.5, median obs.time was 25.4 

mo.). Compared to CD4 lymphocyte deterioration given in the 

literature for patients under antiviral therapy, 52% of our 

patients in Gr. IV exceeded these values, while 24.6% remained 

below. No substantial adverse events or side effects accompanied 

the therapies, thus we found QOL generally increased. CONCLUSIONS: 

Our results suggest that patient performance under a combined and 

individualized naturopathic regimen might be to some extend 

improved with respect to data collected from cohorts in the 

literature. Further investigation including controlled clinical 

trials on different aspects of the single therapies is necessary.